Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels
NCT ID: NCT02215694
Last Updated: 2014-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
128 participants
INTERVENTIONAL
2012-06-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults
NCT02492698
Effect of Different Probiotic Strains in Hypercholesterolemic Patients
NCT04701775
Effect of Probiotics on Lipid Management
NCT03952169
Determination of the Safety and Efficacy of Two Probiotic Strains
NCT06466174
Effects of Synbiotics on Obesity
NCT06578143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
probiotic group
consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
dual probiotics
2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
placebo group
consumed 2g of powder daily without probiotics
placebo
2g of powder daily without probiotics
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dual probiotics
2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
placebo
2g of powder daily without probiotics
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* borderline to moderate hypertriglyceridemia (plasma triglyceride, 150-500 mg/dL)
Exclusion Criteria
* any medications or supplement use
* any probiotics products use for the past 1 months
* dyslipidemia
* diabetes mellitus
* hypertension
* liver disease
* renal disease
* cardiovascular disease
* cerebrovascular disease
* pancreatitis
* cancer
* medication or alcohol abuse
* pregnant or breast feeding
24 Years
68 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jong Ho Lee, PhD
Role: PRINCIPAL_INVESTIGATOR
Yonsei University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory of Clinical Nutrigenetics/Nutrigenomics
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ahn HY, Kim M, Ahn YT, Sim JH, Choi ID, Lee SH, Lee JH. The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects. Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):724-33. doi: 10.1016/j.numecd.2015.05.002. Epub 2015 May 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
probiotics_140801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.